DXVX recently announced on the 23rd that at the '2025 JP Morgan Healthcare Conference' and 'Biotech Showcase 2025' held in San Francisco, USA, it has agreed to continue license discussions with global healthcare and bio companies, as well as to discuss investment proposals and funding procedures with global mega non-profit investment foundations.
DXVX participated in the recent US events alongside faculty from Pohang University of Science and Technology (POSTECH), introducing the world's first mRNA vaccine platform capable of ultra-long-term storage at room temperature, attracting high interest and attention from global companies.
In the second meeting with a global mega bio company, with whom the first meeting was held last year, the company's executive team attended in person to discuss the commercialization potential and cooperation plans for the room temperature ultra-long-term storage mRNA vaccine platform. Notably, a POSTECH professor conducted a seminar on the technology during the meeting, enhancing the credibility and commercialization prospects of the technology.
The room temperature ultra-long-term storage mRNA vaccine platform is known as the world's only technology that fundamentally blocks hydrolysis of the phosphate groups in mRNA, perfectly protecting mRNA under any conditions. Additionally, the extrusion mRNA vaccine mass production process (Extrusion mRNA LNP mass production), co-developed with POSTECH, is an innovative solution that resolves the complex procedures of existing mRNA vaccine production in one go.
The global companies participating in the meeting agreed to activate a working-level consultative body regarding the commercialization process of the mRNA vaccine platform utilizing room temperature storage technology and the extrusion LNP (Lipid Nanoparticle) production process that will bring innovation to mRNA vaccine production. They plan to promptly proceed with follow-up steps for DXVX’s licensing.
Furthermore, DXVX discussed the possibility of licensing agreements for mRNA vaccine LNP production technology through meetings with global companies holding important intellectual property (IP) in the mRNA vaccine industry. In addition, through meetings with more than ten global bio companies, they agreed to promote the DXVX platform and proceed with follow-up steps for licensing agreement discussions.
DXVX also drew positive responses in meetings with global non-profit investment foundations beyond pharmaceutical and bio companies. These non-profit investment foundations are known to have previously invested large-scale funds in various projects such as clinical trials for vaccines and infectious diseases, manufacturing facilities, and factory construction. The global investment foundations highly evaluated DXVX’s technology and commercialization potential and have begun investment discussions to commercialize it, with concrete investment plans expected to be established soon.
DXVX emphasized that the technology introduced at this event opens the possibility of stable vaccine supply even in regions with insufficient medical systems, such as tropical areas. In particular, the technology to store the mRNA substance itself at room temperature is already secured, and business utilizing this technology can proceed immediately. Additionally, technology to coat mRNA with LNP for injectable formulations that can also be stored at room temperature is planned to be secured within this year. This platform can be applied not only to COVID-19 but also to all mRNA-based infectious disease vaccines such as Zika, Dengue, Ebola, Influenza, HIV, and all types of anticancer drugs, making its utility limitless.
DXVX CEO Kwon Kyu-chan stated, "The technology to store the mRNA substance itself at room temperature is already commercially viable, and the LNP technology is rapidly advancing. Through concrete cooperation discussions with global pharmaceutical bio companies and investment foundations at this event, we have further increased the commercialization potential of the technology." He added, "Due to the nature of the platform business, once technology contracts begin, the spread of technology contracts will increase exponentially."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
